Differential Diabetogenic Effect of Pitavastatin and Rosuvastatin, *in vitro* and *in vivo*

Yongin Cho¹, Hyangkyu Lee², Hyun Ki Park², Eun Yeong Choe¹, Hye Jin Wang³, Ryeong-Hyeon Kim¹, Youjin Kim¹ and Eun Seok Kang¹, ³

Yongin Cho and Hyangkyu Lee contributed equally to this work.

¹Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
²Yonsei University College of Nursing, Mo-Im Kim Nursing Research Institute, Biobehavioral Research Center, Seoul, Republic of Korea
³Brain Korea 21 PLUS Project for Medical Science; Yonsei University College of Medicine; Seoul, Korea

**Aim:** Most statins increase the risk of new-onset diabetes. Unlike other statins, pitavastatin is reported to exert neutral effects on serum glucose level, but the precise mechanism is unknown.

**Methods:** Eight-week-old male C57BL/6J mice (*n* = 26) were fed high-fat diet (HFD, 45% fat) with 0.01% placebo, rosuvastatin, or pitavastatin for 12 weeks. Cultured HepG2, C2C12, and 3T3-L1 cells and visceral adipocytes from HFD-fed mice were treated with vehicle or 10 µM statins for 24 h. The effects of pitavastatin and rosuvastatin on intracellular insulin signaling and glucose transporter 4 (GLUT4) translocation were evaluated.

**Results:** After 12 weeks, the fasting blood glucose level was significantly lower in pitavastatin-treated group than in rosuvastatin-treated group (115.2 ± 7.0 versus 137.4 ± 22.3 mg/dL, *p* = 0.024). Insulin tolerance significantly improved in pitavastatin-treated group as compared with rosuvastatin-treated group, and no significant difference was observed in glucose tolerance. Although plasma adiponectin and insulin levels were not different between the two statin treatment groups, the insulin-induced protein kinase B phosphorylation was weakly attenuated in pitavastatin-treated adipocytes than in rosuvastatin-treated adipocytes. Furthermore, minor attenuation in insulin-induced GLUT4 translocation to the plasma membrane of adipocytes was observed in pitavastatin-treated group.

**Conclusion:** Pitavastatin showed lower diabetogenic effects than rosuvastatin in mice that may be mediated by minor attenuations in insulin signaling in adipocytes.

**Key words:** Pitavastatin, Rosuvastatin, Diabetes, Adipocyte, Insulin resistance, Insulin signaling

**Background**

Statins are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors that are proven to be beneficial and widely used for the prevention of cardiovascular diseases.⁵⁻⁷ However, several clinical trials have shown that statins may increase the risk of new-onset diabetes mellitus (NOD).⁵⁻⁷ Although statins cause significant diabetogenic effects, the precise mechanism is incompletely known. Several possible mechanisms have been hypothesized, including the effect of statins on the survival of pancreatic beta cells, reduction in insulin secretion, enhancement in hepatic glucose production, increased insulin resistance through the disruption of intracellular insulin signaling, and disturbance of glucose uptake in the peripheral tissues such as muscle and fat.⁸⁻¹² Whether these effects are common to all statins is questionable.
In comparison with other statins, pitavastatin exhibited neutral effects on serum glucose and NOD risk. In addition, pitavastatin does not appear to increase glucose or glycated hemoglobin level. A recent meta-analysis revealed the absence of any association between pitavastatin and increased risk of NOD.

There are several hypothetical mechanisms explaining the action of pitavastatin on glucose metabolism. The pharmacological profile and effects of pitavastatin on adiponectin were thought to be related to its influence on glucose metabolism. How pitavastatin affects glucose metabolism is, however, still unclear. Here, we investigated the effects of pitavastatin on glucose metabolism by focusing on insulin sensitivity, glucose tolerance, intracellular insulin signaling, and adiponectin levels in diet-induced obese mice and under in vitro conditions.

**Materials and Methods**

**Animals**

Six-week-old male C57BL/6J mice were housed under standard conditions (21 ± 2°C, 60 ± 10% humidity, 12 h light/dark cycle) with ad libitum access to food and water. The mice were fed a high-fat diet (HFD, including 45% fat, n = 6), HFD with rosuvastatin (0.01%, n = 10), or HFD with pitavastatin (0.01%, n = 10) for 12 weeks beginning from 8 weeks of age. Food intake, fasting blood glucose, and body weight were measured twice a week (in the evening after 8 h of fasting). After 12 weeks, the mice were euthanized under anesthesia and the blood samples were collected by cardiac puncture. The liver and epididymal fat tissues were isolated from each mouse and weighed. All animal procedures were performed in accordance with the guidelines from the National Institutes of Health and pre-approved by the animal care and use committee at the Yonsei University, College of Medicine (2014-0304).

**Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)**

OGTT and ITT were performed after the mice had received the test diet for 11 weeks at 19 weeks of age. After 8 h of fasting, the baseline blood glucose level was measured by tail vein puncture. For OGTT, a solution of 40% glucose (2 g/kg body weight) was administered by oral gavage. After glucose administration, blood samples were collected from the tail vein at 15, 30, 60, 90, and 120 min. Blood glucose levels were measured using Accu-Chek Performa glucometer (Boehringer-Mannheim, Indianapolis, IN, USA).

For ITT, the mice were fasted for 8 h under nonanesthetized conditions. Insulin-R (I9278, Sigma-Aldrich, St. Louis, MO, USA) was intraperitoneally injected (0.75 U/kg body weight) and blood samples from the tail vein were collected at 15, 30, 60, 90, and 120 min after insulin injection. Glucose levels were evaluated with Accu-Chek Performa glucometer (Boehringer-Mannheim, Indianapolis, IN, USA).

**Fasting Plasma Insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)**

The blood samples collected after 8 h of fasting were used for the quantification of plasma insulin level with an enzyme-linked immunosorbent assay (ELISA), according to the manufacturer’s recommendations (EZRMI-13K, EMD Millipore Corporation, St. Charles, MO, USA). HOMA-IR was estimated from fasting glucose and insulin as follows:

\[ \text{HOMA-IR} = \frac{\text{fasting insulin (µU/mL)} \times \text{fasting glucose (mg/dL)}}{405} \]

**Measurement of Plasma Total Adiponectin and High Molecular Weight (HMW) Adiponectin Levels**

The blood samples were collected in microcentrifuge tubes and centrifuged to obtain the serum. Serum adiponectin and HMW adiponectin levels were measured using mouse ELISA kits (47-ADPMS-D01, ALPCO, Salem, NH, USA).

**Cell Culture and Drug Treatment**

The hepatocellular carcinoma cell line, HepG2, was cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 mg/mL streptomycin (SV30010) in a 5% CO2 incubator at 37°C. The immortalized murine myoblast cell line, C2C12, was cultivated in Eagle’s Minimum Essential Medium supplemented with 2 mM L-glutamine, 10% dialyzed FBS, and antibiotics. Preadipocyte 3T3-L1 cells were cultured in a differentiation medium. Rosuvastatin (SML1264, Sigma-Aldrich, St. Louis, MO, USA) and pitavastatin (CAS 147526-32-7, Santa Cruz Biotechnology, Santa Cruz, CA, USA) were dissolved in dimethyl sulfoxide before dilution in the culture medium. In all experiments, the final statin and dimethyl sulfoxide concentrations were 10 µM and 0.1%, respectively.

**Western Blot Analysis for Protein Kinase B (Akt) and Phosphorylated Akt**

Primary adipocytes from the mouse visceral adipose tissue and 3T3-L1, HepG2, and C2C12 cells were pretreated with 10 µM pitavastatin or rosuvastatin for 24 h, serum-starved for 4 h with or without statins, and stimulated with 100 nM insulin for 5 to 15 min. Cell lysates were obtained from each treat-
Statistical Analysis
All data are presented as the mean ± standard deviation (SD). Statistical analyses were performed with t-test, analysis of variance (ANOVA), or repeated measures ANOVA with Dunnett’s t-test for multiple comparisons as appropriate. A value of p < 0.05 was considered significant. Analysis was performed using SPSS Statistics version 23.0 (IBM Co., Somers, NY, USA).

Results
Biochemical Characteristics of Mice
The characteristics of mice from different groups are described in Table 1. Baseline body weight was the lowest among the mice from rosuvastatin group. At the end of the treatment (after 12 weeks), no difference was observed in the body weight and degree of weight gain between all groups. Furthermore, the mean liver weight and fat mass were not significantly different among the mice from the three groups (all p > 0.05).

No difference in body weight gain was observed between pitavastatin and rosuvastatin treatment groups over the 12-week study period (Fig. 1a). No statistical difference was reported in food intake among the three groups (Fig. 1b). However, fasting blood glucose level was significantly lower in pitavastatin group than in rosuvastatin group after 12 weeks of treatment (115.2 ± 7.0 mg/dL in pitavastatin group versus 137.4 ± 22.3 mg/dL in rosuvastatin group, p = 0.024, Fig. 1c).

Effects of Pitavastatin and Rosuvastatin on Glucose and Insulin Tolerance
The results of OGTT showed that the mice from pitavastatin group exhibited a significant improvement in glucose tolerance as compared with those from control and rosuvastatin groups at 0, 30, and
120 min after glucose administration (all $p<0.05$, Fig. 2a). The area under the curve (AUC) value of OGTT was lower for pitavastatin group than for HFD and rosuvastatin groups, but no statistically significant difference was reported (Fig. 2b, $p=0.080$).

Insulin tolerance improved in pitavastatin group as compared with the control group at 15 and 60 min after insulin administration (all $p<0.05$, Fig. 2c). Furthermore, the AUC value of ITT significantly reduced in both pitavastatin and rosuvastatin groups (Fig. 2d, $p=0.008$ for pitavastatin and $p=0.013$ for rosuvastatin).

Effects of Pitavastatin and Rosuvastatin on Plasma Insulin and Insulin Resistance

The mean plasma insulin concentration was 11.2, 9.2, and 8.8 $\mu$U/mL in the control, rosuvastatin, and pitavastatin groups, respectively (Fig. 3a). No significant difference was reported between the three groups, although the plasma insulin level tended to be lower in pitavastatin group than in other groups ($p=0.138$). Insulin resistance, as indicated by HOMA-IR value, was the lowest in pitavastatin group ($p=0.048$, Fig. 3b).

Effects of Pitavastatin and Rosuvastatin on Plasma Adiponectin and HMW Adiponectin Levels

The plasma adiponectin level increased in pitavastatin group as compared to the control and rosuvastatin groups, although no significant difference was reported ($21,779.9 \pm 3,317.5$, $17,409.2 \pm 3,453.3$, and $20,139.6 \pm 2,070.8$ ng/dL in pitavastatin, HFD, and rosuvastatin groups, respectively; $p=0.105$) (Fig. 4a). No significant differences were observed in HMW adiponectin levels between the three groups ($p=0.653$, Fig. 4b).

Effects of Pitavastatin and Rosuvastatin on Insulin Signaling

To analyze the effect of pitavastatin on insulin response in the liver, we evaluated the phosphorylation level of Akt after 15 min from stimulation of HepG2 cells with insulin. No significant difference was observed in the level of Akt phosphorylation at serine 473 and threonine 308 among the three insulin-stimulated groups (all $p>0.05$ versus control insulin group, Fig. 5a).

Intracellular insulin signaling level in the muscle was analyzed using C2C12 cells (Fig. 5b). After 15 min of insulin administration, no significant difference was observed in the level of Akt phosphorylation at serine 473 and threonine 308 in HepG2 cells from the three groups (all $p>0.05$ versus control + insulin group, Fig. 5a).

To confirm the role of statins in the adipose tissue, intracellular insulin signaling was investigated in 3T3-L1 adipocytes (after differentiation). After insulin stimulation, Akt phosphorylation level at serine 473 and threonine 308 showed attenuated pattern in rosuvastatin-treated cells as compared with control cells (Fig. 5c). Akt phosphorylation at serine 473 showed a decreasing trend in rosuvastatin group as compared
leads to a decrease in glucose uptake. In 3T3-L1 cells, the reduction in 2-DG uptake was observed in rosuvastatin group (versus control \( p < 0.042 \), Fig. 6a).

GLUT4 staining showed a significant increase in the translocation of GLUT4 to the membrane after insulin administration in pitavastatin group than in rosuvastatin group (Fig. 6b). These observations confirm that the difference in glucose uptake between adipocytes may arise from the variations in GLUT4 translocation to the plasma membrane.

Discussion

In the present study, we evaluated the effects of pitavastatin on glucose metabolism in HFD-fed obese mice and several cell lines and compared them with the effects of a widely used drug, rosuvastatin. In comparison with rosvu
Fig. 3. Plasma insulin levels and HOMA-IR in different treatment groups
(a) Insulin level. (b) HOMA-IR. Error bars represent standard error of mean. *p<0.05 versus corresponding HFD value. All p values were generated by ANOVA. HFD, high-fat diet; Pitava, pitavastatin; Rosuva, rosuvastatin; HOMA-IR, homeostatic model assessment of insulin resistance.

Fig. 4. Plasma adiponectin and high molecular weight (HMW) adiponectin level in different treatment groups
(a) Total adiponectin. (b) HMW adiponectin. Error bars represent standard error of mean. P values were generated by ANOVA. HFD, high-fat diet; Pitava, pitavastatin; Rosuva, rosuvastatin.

Fig. 5. Statins differentially alter the insulin-induced phosphorylation of Akt in cultured cells
Cells were treated with 10 µM of statins for 24 h, followed by insulin stimulation for 5 to 15 min. (a) HepG2 cells, (b) C2C12 cells, (c) 3T3-L1 cells. Representative western blots are shown above the plots of densitometric analysis of p-Akt/Akt ratio in relation to insulin-stimulated control group (means ± SE, n=3-4). Dunnett’s t-test was used to compare the values of statin-treated groups and insulin-stimulated control group. *p<0.05 versus control + insulin. Con, control; Pit, pitavastatin; Ros, rosuvastatin; Ins, insulin; SE, standard error.
and increased systemic bioavailability (≥ 51%) and it may strongly influence the systemic glucose uptake in peripheral cells such as myocytes and adipocytes\(^{17}\). However, in the present study, we found that the use of pitavastatin did not significantly affect the process of insulin signaling in the muscle or adipose tissue. This may serve as one of the reasons underlying the neutral effects of pitavastatin on glucose metabolism.

Insulin signaling in the peripheral adipose tissue is mediated by the binding of insulin to the cell surface receptors, resulting in the phosphorylation of insulin receptor substrates at specific tyrosine residues and activation of phosphatidylinositol 3-kinase 3-kinase and its downstream target Akt. Akt and the downstream targets have key roles in insulin sensitivity and normal glucose tolerance\(^{23, 24}\). Phosphoinositide-3,4,5-trisphosphate produced by phosphatidylinositol 3-kinase\(^{25}\) binds to the domain of Akt, allowing for its translocation to the cell membrane, followed by phosphorylation and activation within the catalytic domain T-loop (threonine 308) and the carboxyl terminal hydrophobic domain (serine 473) and the subsequent activation of many downstream targets\(^{26, 27}\). In the next step, it redistributes GLUT4 from the intracellular storage to the plasma membrane. Therefore, the reduction in Akt activation in the adipose tissue may potentially increase insulin resistance and the risk of diabetes. In addition, the differences in the expression of GLUT4 in adipocytes were thought to be one of the reasons for the observed differences in the effects of statins on glucose metabolism\(^{28}\). However, in the present study, the attenuation of Akt phosphorylation in adipocytes was lower in the presence of pitavastatin than with rosuvastatin treatment. In addition, the difference in Akt attenuation between pitavastatin and rosuvastatin groups led to the variation in GLUT4 translocation to the plasma membrane and 2-DG uptake in adipocytes.

Previous studies have reported attenuated insulin signaling and decreased GLUT4 translocation in adipocytes when using atorvastatin\(^{29}\) or lovastatin\(^{30}\). In this study, rosuvastatin also showed a similar effect, while pitavastatin did not show such patterns. Previous studies in humans have shown increased insulin resistance following treatment with several statins, including rosuvastatin\(^{31}\). However, consistent with present study, pitavastatin was shown to exert no effect on blood glucose control and whole body insulin sensitivity\(^{32}\). The mechanisms by which some statins may exert diabetogenic effects currently remain unclear. Several recent meta-analyses have suggested that a differential effect on incidence of diabetes\(^{33}\) or insulin sensitivity\(^{34}\) may exist for different statins in human. Statins comprise many subtypes based on structural

![Fig. 6. Statins differentially alter the insulin-induced 2-DG uptake and GLUT4 translocation in cultured adipocytes](image)

(a) Comparison of 2-DG uptake. Data represent means ± SE of three independent experiments and are expressed as fold changes in glucose uptake relative to that with control + insulin group. Dunnett’s \(t\)-test was used to compare the values of statin-treated groups and insulin-stimulated control group. *\(p<0.05\), **\(p<0.01\)

(b) GLUT4 staining. A, Con; B, Con + Ins; C, Pit + Ins; D, Ros + Ins. GFP is shown in green (Scale bar: 10 µm (micrometer)). GLUT4, glucose transporter 4; 2-DG, 2-deoxyglucose; Con, control; Pit, pitavastatin; Ros, rosuvastatin; Ins, insulin; SE, standard error; GFP, green fluorescent protein.
differences, resulting in different pharmacokinetics and efficacy. This structural difference between statins could lead to a difference in efficiency in transportation into the cell and differential diabetogenic effect.

Clinical data have shown that pitavastatin increases plasma adiponectin and HMW adiponectin levels, which are potent insulin sensitizers. This phenomenon is often presented as one of the important reasons underlying the lower risk of diabetes with pitavastatin than with other statins. However, in the present study, no statistically significant difference was observed in the serum levels of adiponectin and HMW adiponectin in different treatment groups. The present findings provide evidence that pitavastatin exerts neutral effects on insulin signaling and resistance without changing the levels of adiponectin. In previous studies, the possibility that the use of pitavastatin may directly act on fat tissue via prevention of adipocyte hypertrophy and anti-adipogenic action was reported. We could not proceed with a related experiment in the current study, and instead, we measured the size of adipocyte (visceral) using a similar design model from a study conducted in our laboratory. The results also showed that the cell size in adipose tissue of pitavastatin treatment group was significantly decreased compared to the high fat control or rosuvastatin treatment group (all p < 0.001 by ANOVA, Supplementary Fig. 2). Likewise, the result of this study was consistent with those of previously reported studies in that the difference in the effect of pitavastatin on glucose metabolism, as compared with other statins, is mainly associated with the variation in its effect on adipocytes.

In vitro experiments revealed the lack of any significant difference in insulin signaling in hepatocytes and muscle cells from pitavastatin and rosuvastatin treatment groups. Only adipocytes from pitavastatin treatment group were less affected during insulin signaling and were less involved in insulin resistance compared to those from rosuvastatin treatment group. Recent studies on statins have reported increased insulin resistance in adipose tissue. Henriksbo et al. reported that statin activates caspase-1/IL-1β inflammasome responses and impairs endocrine control of adipocyte lipogenesis. However, further studies will be needed to determine why these effects are specific for adipocytes.

In the current study, insulin-responsive secretion evoked by increased insulin resistance was not observed in rosuvastatin group. Increased insulin resistance with persistent high-fat diets could decrease the function of insulin secretion in rosuvastatin group. Also, hepatic gluconeogenesis plays an important role in determining fasting insulin level, as well as the function of beta cell secretion. In this study, there was no significant difference in the effect of statin on liver. As a result, this may lead to similar fasting insulin levels. However, the direct effect of statins on the pancreas and the function of insulin secretion was not fully investigated in this study, and further studies will be needed to complement these factors.

The present study also had several other limitations. The change in serum cholesterol level was not measured. Therefore, whether the experiment was performed under the conditions that produce similar effects on cholesterol remains a concern. In addition, the effect of pitavastatin was compared only with rosuvastatin; we could not confirm whether similar results could be reproducible with other statins. Despite these limitations, the study has several merits. We investigated the effects of pitavastatin on glucose metabolism via intracellular insulin signaling, insulin resistance, and glucose clearance in HFD-induced obese mice and several cell lines. Furthermore, we demonstrated that pitavastatin is less involved in the increased peripheral insulin resistance through the decreased attenuation of insulin-stimulated intracellular signaling via Akt phosphorylation and GLUT4 translocation.

Conclusion

Pitavastatin treatment reduced fasting blood glucose and insulin resistance than rosuvastatin treatment. This observation was associated with the improvement in peripheral insulin resistance, especially in the adipose tissue, via intracellular Akt activation and GLUT4 translocation. Pitavastatin may serve as a useful drug for the treatment of dyslipidemia in patients with a high risk of insulin resistance or hyperglycemia.

List of Abbreviations

GLUT4, glucose transporter 4; NOD, new-onset diabetes mellitus; HFD, high-fat diet; OGTT, oral glucose tolerance test; ITT, insulin tolerance test; HOMA-IR, homeostatic model assessment of insulin resistance; HMW, high molecular weight; Akt, protein kinase B; 2-DG, 2-deoxyglucose; AUC, area under the curve.

Declarations

Ethics approval and consent to participate: All animal procedures were performed in accordance with the guidelines from the National Institutes of Health.
and pre-approved by the animal care and use committee at the Yonsei University, College of Medicine (2014-0304).

Consent for Publication
Not applicable.

Availability of Data and Material
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflict of Interest
The authors declare that they have no conflict of interest.

Funding
This work was supported by a faculty research grant of Yonsei University College of Medicine (6-2017-0053) and the Bio & Medical Technology Development Program of the NRF, Korea, MSIP (2016R1A2B4013029) to E.S. Kang, and Basic Science Research Program through the NRF, Korea by the Ministry of Education (2015R1D1A10905895) to H. Lee.

Acknowledgement
We thank Editage (www.editage.com) for English language editing and publication support.

Authors’ Contributions
Y. Cho, E.Y. Choe, H. Lee and E. S. Kang designed the experiment, interpreted the experimental results, and wrote the manuscript. H. Park, H.J. Wang, R-H Kim, and Y. Kim designed and conducted the experiments. H. Lee and E. S. Kang revised the manuscript. All authors contributed to manuscript preparations & discussion and approved the final manuscript.

References
1) Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J and Collins R: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681
2) O’Regan C, Wu P, Arora P, Perri D and Mills EJ: Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med, 2008; 121: 24-33
3) Sever PS, Dahlof B, Poulter NR, Wedel H, Beever G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlisen J, Nieminen M, O’Brien E and Ostergren J: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003; 361: 1149-1158
4) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002; 360: 7-22
5) Sattar N, Preiss D, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N and Ray KK: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a collaborative meta-analysis of randomised statin trials. Lancet, 2010; 375: 735-742
6) Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N and Ray KK: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA, 2011; 305: 2556-2564
7) Sattar NA, Ginsberg H, Ray K, Chapman MJ, Arca M, Avenna M, Betteridge DJ, Bhattacharjee D, Bilianou E, Carmanina R, Ceska R, Corsini A, Erbel R, Flynn PD, Garcia-Moll X, Gumprecht J, Ishibashi S, Jambart S, Kastelein JJ, Maheer Y, da Silva PM, Masana L, Odaawara M, Pedersen TR, Rotella CM, Salti I, Taramo T, Tokgozoglu L, Toth PP, Valensi P and Verges B: The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Atheroscler Suppl, 2014; 15: 1-15
8) Betteridge DJ and Carmen R: The diabetogenic action of statins - mechanisms and clinical implications. Nat Rev Endocrinol, 2016; 12: 99-110
9) Lorza-Gil E, Salerno AG, Wanschel AC, Vettorazzi JF, Ferreira MS, Rontz T, Catharino RR and Oliveira HC: Chronic use of pravastatin reduces insulin exocytosis and increases beta-cell death in hypercholesterolemic mice. Toxicology, 2016; 344-346: 42-52
10) Wang HJ, Park KJ, Kwon O, Choe EY, Kim CH, Hur KY, Lee MS, Yun M, Cha BS, Kim YB, Lee H and Kang ES: Chronic HMGCR/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction. Autophagy, 2015; 11: 2089-2101
11) Brault M, Ray J, Gomez YH, Mantzoros CS and Daskalopoulou SS: Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism, 2014; 63: 735-745
12) Colbert JD and Stone JA: Statin use and the risk of incident diabetes mellitus: a review of the literature. Can J Cardiol, 2012; 28: 581-589
13) Yamakawa T, Takano T, Tanaka S, Kadonosono K and Terauchi Y: Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb, 2008; 15: 260-275
14) Gumprecht J, Gosho M, Budinski D and Hounslow N: Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab, 2011; 13: 1047-1055
15) Koshiyama H, Taniguchi A, Tanaka K, Kagimoto S, Fujioka Y, Hirata K, Nakamura Y, Iwakura A, Hara K, Yamamoto T, Kuroe A, Ohya M, Fujimoto S, Hamamoto Y, Honjo S, Ikeda H, Nabe K, Tsuda K, Inagaki N, Seino Y and Kume N: Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigators. J Atheroscler Thromb, 2008; 15: 345-350
16) Vallejo-Vaz AJ, Kondapally Seshasai SR, Kurogi K, Michishita I, Nozue T, Sugiyama S, Tsimikas S, Yoshida H and Ray KK: Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis, 2015; 241: 409-418
17) Arnaboldi L and Corsini A: Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atheroscler Suppl, 2015; 16: 1-27
18) Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF and Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28: 412-419
19) Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A and Mann M: Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics, 2002; 1: 376-386
20) Viravaidya K and Shuler ML: Incorporation of 3T3-L1 cells to mimic bioaccumulation in a microscale cell culture analog device for toxicity studies. Biotechnol Prog, 2004; 20: 590-597
21) Trevelin E, Scorzeto M, Olivieri M, Granzotto M, Valerio A, Tedesco L, Fabris R, Serra R, Quarta M and Reggiani C: Exercise training induces mitochondrial biogenesis and glucose uptake in subcutaneous adipose tissue through eNOS-dependent mechanisms. Diabetes, 2014; DB_131234
22) Corsini A and Ceska R: Drug-drug interactions with statins: will pitavastatin overcome the statins’ Achilles’ heel? Curr Med Res Opin, 2011; 27: 1551-1562
23) Cho H, Thorvaldsen JL, Chu Q, Feng F and Birnbaum MJ: Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem, 2001; 276: 38349-38352
24) Chen S, Wasserman DH, MacKintosh C and Sakamoto K: Mice with As160/TBC1D4-Thr649Ala knockin mutation are glucose intolerant with reduced insulin sensitivity and altered GLUT4 trafficking. Cell Metab, 2011; 13: 68-79
25) Khan AH and Pessin JE: Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. Diabetologia, 2002; 45: 1475-1483
26) Gonzalez E and McGraw TE: Insulin-modulated Akt subcellular localization determines Akt isoform-specific signaling. Proc Natl Acad Sci U S A, 2009; 106: 7004-7009
27) Manning BD: Insulin signaling: inositol phosphates get into the Akt. Cell, 2010; 143: 861-863
28) Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S and Yada T: Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycemic control. Diabetologia, 2006; 49: 1881-1892
29) Takaguri A, Satoh K, Itagaki M, Tokumitsu Y and Ichihara K: Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3-L1 adipocytes. Journal of pharmacological sciences, 2008; 107: 80-89
30) Mcguire TF, Xu X-Q, Corey SJ, Romero GG and Sebti SM: Lovastatin disrupts early events in insulin signaling: A potential mechanism of lovastatins anti-mitogenic activity. Biochemical and biophysical research communications, 1994; 204: 399-406
31) Moutzouri E, Liberopoulos E, Mikhailidis D, Kostapanos M, Kei A, Milionis H and Elisa M: Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. International journal of clinical practice, 2011; 65: 1141-1148
32) Braun LR, Feldpausch MN, Czerwonka N, Weiss J, Branch K, Lee H, Martinez-Salazar EL, Torriani M, Sponseller CA and Grinspoon SK: Effects of Pitavastatin on Insulin Sensitivity and Liver Fat: A Randomized Clinical Trial. The Journal of Clinical Endocrinology & Metabolism, 2018; 103: 4176-4186
33) Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, Caputo S, Grzesk G, Kubica A and Swiatkiewicz I: Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. The American journal of cardiology, 2013; 111: 1123-1130
34) Baker WL, Talati R, White CM and Coleman CI: Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes research and clinical practice, 2010; 87: 98-107
35) Schachter M: Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundamental & clinical pharmacology, 2005; 19: 117-125
36) Kurogi K, Sugiyama S, Sakamoto K, Tayama S, Nakamura S, Biwa T, Matsui K and Ogawa H: Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study. J Cardiol, 2013; 62: 87-94
37) Nomura S, Inami N, Shouzu A, Omoto S, Kimura Y, Takahashi N, Tanaka A, Urase F, Maeda Y, Ohtani H and Iwaska T: The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets, 2009; 20: 16-22
38) Inami N, Nomura S, Shouzu A, Omoto S, Kimura Y, Takahashi N, Tanaka A, Nanba M, Shouda Y and Iwasaka T: Effects of pitavastatin on adiponectin in patients with hyperlipidemia. Pathophysiol Haemost Thromb, 2007; 36: 1-8
39) Matsubara T, Naruse K, Arakawa T, Nakao M, Yokoi K, Oguri M, Marui N, Amano T, Ichimiya S, Ohashi T, Imai K, Sakai S, Sugiyama S, Ishii H and Murohara T: Impact of pitavastatin on high-sensitivity C-reactive protein and adiponectin in hypercholesterolemic patients with the metabolic syndrome: the PREMIUM Study. J Cardiol, 2012; 60: 389-394
40) Fisher FM, Trujillo ME, Hanif W, Barnett AH, McTernan PG, Scherer PE and Kumar S: Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia, 2005; 48: 1084-1087
41) Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, Imai Y, Nagai R and Kadowaki T: Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care, 2006; 29: 1357-1362
42) Ishihara Y, Ohmori K, Mizukawa M, Hasan AU, Noma T and Kohno M: Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice. Atherosclerosis, 2010; 212: 131-138
43) Nicholson A, Hajjar D, Zhou X, He W, Gotto A and Han J: Anti-adipogenic action of pitavastatin occurs through the coordinate regulation of PPARy and Pref-1 expression. British journal of pharmacology, 2007; 151: 807-815
44) Henriksbo BD, Tamrakar AK, Xu J, Duggan BM, Cavalieri JF, Phulka J, Stampfli MR, Ashkar AA and Schertzer JD: Statins Promote IL-1β-Dependent Adipocyte Insulin Resistance via Lower Prenylation not Cholesterol. Diabetes, 2019; db180999
**Supplementary Fig. 1.** Statins differentially alter the insulin-induced phosphorylation of Akt in cultured cells

Primary adipocytes from the visceral fat tissue were treated with 10 µM of statins for 24 h, followed by stimulation with insulin for 5 to 15 min. (a) Visceral adipocytes from mice fed with high-fat diet. Representative western blots are shown above the plots of densitometric analysis of p-Akt/Akt ratio in relation to insulin-stimulated control cells (means ± SE, n=2). Dunnett’s t-test was used to compare the values between statin-treated groups and insulin-stimulated control group. *p < 0.05 versus control + insulin. Con, control; Pit, pitavastatin; Ros, rosuvastatin; Ins, insulin.

**Supplementary Fig. 2.** Statins differentially alter the size of adipocytes

Mice were fed a high-fat diet (HFD, including 45% fat, n=4), HFD with rosuvastatin (0.01%, n=3), or HFD with pitavastatin (0.01%, n=3) for 15 weeks, starting from 5 weeks of age. Graph data were compiled to show the effects of pitavastatin and rosuvastatin on the diameter of adipocytes in a total of 1,200 adipocytes (n=120 per animal). Markedly increased size of adipocytes were observed in both high fat control group and rosuvastatin treated group with high fat diet, but the sizes were less increased in pitavastatin treated group with high fat diet mouse model (all p < 0.001 by ANOVA test). HFD, high fat diet control; Pitava, pitavastatin treated with high fat diet; Rosuva, rosuvastatin treated with high fat diet.